What's Going On With Canopy Growth Stock Thursday?
Canopy Growth Corp (NASDAQ:CGC) shares are falling Thursday morning, pulling back following Wednesday’s strength, after a potential major shift in U.S. cannabis policy put the sector in focus. Here’s what investors need to know.
- Canopy Growth shares are falling. What’s fueling CGC momentum?
What Is the Catalyst for Canopy Growth?
A Trump administration official told Axios the White House is expected to reclassify marijuana as early as Wednesday, following an executive order last year to move marijuana to Schedule III. The change is viewed as a catalyst for Canopy's medical strategy because it could ease DEA barriers around research and clinical work.
The impending reclassification could ease U.S. Drug Enforcement Administration barriers to researching the drug's potential use cases. For an industry leader like CGC with established infrastructure, the move would make it easier to study medicinal applications of marijuana.
Canopy Growth Technical Levels To Watch
Canopy Growth is still in "rebuild mode" within its 52-week range, sitting well below the $2.38 high and above the 84 cents low, which keeps the longer-term picture more range-bound than breakout-driven. The stock is trading 42.1% above its 20-day simple moving average (SMA) and 29.9% above its 100-day SMA, which leans toward strong near-term momentum carrying into the intermediate trend.
The moving-average structure is still mixed because the 20-day SMA is below the 50-day SMA, and the death cross from November 2025 (50-day below the 200-day) is a reminder the longer trend only recently started stabilizing. At the same time, price is now 22.7% above the 200-day SMA, which is consistent with buyers defending the longer-term trend line more aggressively.
The relative strength index (RSI), a momentum gauge, is 73.32, which is overbought and often lines up with "hot" rallies that can cool quickly. RSI at 73.32 means upside pressure has been strong lately, but pullbacks can show up faster than usual.
- Key Resistance: $1.50 — where recent rallies have tended to stall and sellers show up
- Key Support: $1.00 — a floor area where demand has previously appeared
What Does Canopy Growth Do?
Canopy Growth cultivates and sells medicinal and recreational cannabis and hemp through brands including Doja, LivRelief, Ace Valley, Deep Space, and others. It operates across Canada cannabis, International markets cannabis, Storz & Bickel, and This Works, with its largest revenue contribution coming from Canadian cannabis.
That mix helps explain why U.S. regulatory headlines can still move the stock: any shift that lowers federal friction around medical cannabis research can change how investors think about Canopy's longer-term optionality. The current focus is less about near-term sales and more about whether easier research pathways can support product development and medical positioning over time.
Canopy Growth's setup is also being framed as "infrastructure already in place," with investors leaning into the idea that easier research rules could help validate product pipelines and clinical work with fewer federal hurdles. That's the core reason the stock can react sharply to a Schedule III headline even before any revenue impact shows up.
Canopy Growth Earnings Preview For May
Looking further out, the next major catalyst for the stock arrives with the May 29 (estimated) earnings report.
- EPS Estimate: Loss of 6 cents (Up from $-1.01 YoY)
- Revenue Estimate: $53.26 million (Up from $45.75 million YoY)
CGC Stock Price Activity Thursday Morning
CGC Price Action: Canopy Growth shares were down 5.07% at $1.31 at the time of publication on Thursday, according to Benzinga Pro data.
Image: Shutterstock